Bolt Biotherapeutics is a clinical-stage biotechnology company that develops cancer treatments. The company was founded in 2015 and is headquartered in South San Francisco, California. Bolt's platform uses immune-stimulating antibody conjugates to target tumors and activate the immune system. The company's lead product candidate, BDC-1001, is being evaluated in clinical trials for the treatment of solid tumors. Bolt has received funding from investors such as Novo Holdings, Pivotal bioVenture Partners, and RA Capital Management.
Highest paying job titles at Bolt Biotherapeutics include Director, Biostatistics, Medical Director, and Principal Scientist